Sarepta Therapeutics: Navigating Elevidys Upside Potential

Kagenmi/iStock via Getty Images Sarepta Therapeutics, Inc. (NASDAQ:SRPT), submitted a request to the FDA aiming to erase the ambulation and age restrictions for Elevidys, as well as a switch in the designation from accelerated to standard approval. The company reported, in its Q1 2024 conference call, that the FDA will be issuing a response by June 21st or earlier. SRPT's management seems very certain about their chances to obtain the label expansion. However, I believe the FDA has enough grounds to support ...